Your browser doesn't support javascript.
loading
Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans.
Mateza, Somila; Bradford, Yuki; Maartens, Gary; Sokhela, Simiso; Chandiwana, Nomathemba C; Venter, Willem D F; Post, Frank A; Ritchie, Marylyn D; Haas, David W; Sinxadi, Phumla.
  • Mateza S; Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.
  • Bradford Y; Department of Genetics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Maartens G; Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.
  • Sokhela S; Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town.
  • Chandiwana NC; Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Venter WDF; Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Post FA; Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Ritchie MD; Department of Sexual Health and HIV, King's College Hospital NHS Foundation Trust.
  • Haas DW; Department of Infectious Diseases, King's College London, UK.
  • Sinxadi P; Department of Genetics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Pharmacogenet Genomics ; 33(5): 91-100, 2023 07 01.
Article en En | MEDLINE | ID: mdl-37099271
ABSTRACT

OBJECTIVE:

Renal toxicity is more common with tenofovir disoproxil fumarate (TDF) than with tenofovir alafenamide fumarate (TAF). We investigated whether polymorphisms in genes relevant to tenofovir disposition affect renal toxicity among HIV-positive Southern Africans.

METHODS:

Genetic sub-study of adults randomized to initiate TAF or TDF together with dolutegravir and emtricitabine was conducted. Outcomes were changes from week 4 to 48 in the estimated glomerular filtration rate (eGFR) and from baseline to week 48 in urine retinol-binding protein and urine ß2-microglobulin adjusted for urinary creatinine (uRBP/Cr and uB2M/Cr). Primary analyses prioritized 14 polymorphisms previously reported to be associated with tenofovir disposition or renal outcomes, and all polymorphisms in 14 selected genes. We also explored genome-wide associations.

RESULTS:

336 participants were enrolled. Among 14 polymorphisms of primary interest, the lowest P values for change in eGFR, uRBP/Cr, and uB2M/Cr were ABCC4 rs899494 ( P  = 0.022), ABCC10 rs2125739 ( P  = 0.07), and ABCC4 rs1059751 ( P  = 0.0088); and in genes of interest, the lowest P values were ABCC4 rs4148481 ( P  = 0.0013), rs691857 ( P  = 0.00039), and PKD2 rs72659631 ( P  = 0.0011). However, none of these polymorphisms withstood correction for multiple testing. Genome-wide, the lowest P values were COL27A1 rs1687402 ( P  = 3.4 × 10 -9 ), CDH4 rs66494466 ( P  = 5.6 × 10 -8 ), and ITGA4 rs3770126 ( P  = 6.1 × 10 -7 ).

CONCLUSION:

Two ABCC4 polymorphisms, rs899494 and rs1059751, were nominally associated with change in eGFR and uB2M/Cr, respectively, albeit in the opposite direction of previous reports. COL27A1 polymorphism was genome-wide significantly associated with change in eGFR.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / Seropositividad para VIH / Fármacos Anti-VIH / Tenofovir Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / Seropositividad para VIH / Fármacos Anti-VIH / Tenofovir Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Año: 2023 Tipo del documento: Article